A phase 2 biomarker study evaluating subjects with unresected, advanced melanoma treated with talimogene laherparepvec

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-005552-15

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To explore the correlation between a baseline immunoprofile (ie, intratumoral CD8+ cell density) and objective response rate (ORR) in subjects with unresected stage IIIB to IVM1c melanoma treated with talimogene laherparepvec.


Critère d'inclusion

  • Unresected Stage IIIB to IVM1c Melanoma